Contemporary Interpretations of Ophthalmological Manifestations of Chronic Myeloproliferative Neoplasms

Cover Page


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The course of chronic myeloproliferative neoplasms (CMPN), a group of systemic hematological diseases, can be accompanied by various complications and changes in tissues and organs of the whole organism. The eye is the only organ where damage of nerve fibers and blood vessels can be directly observed and examined, and ocular symptoms can be the initial, manifest of systemic pathology, the toxic effects of modern targeted therapy, or the first manifestation of a relapse of the disease after treatment. The most frequently described manifestations are caused by hematological anomalies that cause microvascular disorders. Such changes today remain insufficiently studied in terms of the using new research methods and contemporary targeted therapy. In addition, ocular symptoms may precede more serious extraocular complications. Combined ophthalmological and hematological examination of patients with CMPN can become a preventive approach for early diagnosis and timely treatment.

Full Text

Restricted Access

About the authors

Larisa K. Moshetova

Russian Medical Academy of Continuous Professional Education

Author for correspondence.
Email: moshetovalk@yandex.ru
ORCID iD: 0000-0002-5899-2714
SPIN-code: 5697-6825

MD, PhD, Professor, Academician of the RAS

Russian Federation, Moscow

Lidia B. Egoryan

Russian Medical Academy of Continuous Professional Education; Moscow Ophthalmology Center of Botkin City Clinical Hospital

Email: legoryan@yandex.ru
ORCID iD: 0000-0001-8077-5225
SPIN-code: 9437-9184

PhD Student

Russian Federation, Moscow; Moscow

Olga J. Vinogradova

Pirogov Russian National Research Medical University; Moscow Hematology Center of Botkin City Clinical Hospital; Rogachev National Medical Research Center for Pediatric Hematology

Email: olgavinz@mail.ru
ORCID iD: 0000-0002-3669-0141
SPIN-code: 7195-5351

MD, PhD, Professor

Russian Federation, Moscow; Moscow; Moscow

Ksenia I. Turkina

Russian Medical Academy of Continuous Professional Education; Moscow Ophthalmology Center of Botkin City Clinical Hospital

Email: kseniyait@mail.ru
ORCID iD: 0000-0002-4989-7467
SPIN-code: 3187-4280

MD, PhD

Russian Federation, Moscow; Moscow

Dgariat I. Shikhbabaeva

Moscow Hematology Center of Botkin City Clinical Hospital

Email: d.shikhbabaeva@yandex.ru
ORCID iD: 0000-0002-1384-1621
SPIN-code: 6023-3313

MD, PhD

Russian Federation, Moscow

References

  1. Khoury JD, Solary E, Abla O, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. Leukemia. 2022;36(7):1703–1719. doi: https://doi.org/10.1038/s41375-022-01613-1
  2. Rampal R, Al-Shahrour F, Abdel-Wahab O, et al. Integrated Genomic Analysis Illustrates the Central Role of JAK-STAT Pathway Activation in Myeloproliferative Neoplasm Pathogenesis. Blood. 2014;123(22):е123–133. doi: https://doi.org/10.1182/blood-2014-02-554634
  3. Nangalia J, Massie CE, Baxter EJ, et al. Somatic CALR Mutations in Myeloproliferative Neoplasms with Nonmutated JAK2. N Engl J Med. 2013;369(25):2391–2405. doi: https://doi.org/10.1056/NEJMoa1312542
  4. Klampfl T, Gisslinger H, Harutyunyan AS. Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms. N Engl J Med. 2013;369(25):2379–2390. doi: https://doi.org/10.1056/NEJMoa1311347
  5. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209–249. doi: https://doi.org/10.3322/caac.21660
  6. Shuvaev V, Martynkevich I, Abdulkadyrova A, et al. Ph-Negative Chronic Myeloproliferative Neoplasms – Population Analysis, a Single Center 10-years’ Experience. Blood. 2014;124(21):5556. doi: https://doi.org/10.1182/blood.v124.21.5556.5556
  7. Yang HS, Joe SG, Kim J‐G, et al. Delayed Choroidal and Retinal Blood Flow in Polycythaemia Vera Patients with Transient Ocular Blindness: A Preliminary Study with Fluorescein Angiography. Br J Haematol. 2013;161(5):745–747. doi: https://doi.org/10.1111/bjh.12290
  8. Billot S, Kouroupi EG, Le Guilloux J, et al. Neurological Disorders in Essential Thrombocythemia. Haematologica. 2011;96(12):1866–1869. doi: https://doi.org/10.3324/haematol.2011.050005
  9. Dhasmana R, Prakash A, Gupta N, et al. Ocular manifestations in leukemia and myeloproliferative disorders and their association with hematological parameters. Ann Afr Med. 2016;15(3):97–103. doi: https://doi.org/10.4103/1596-3519.188887
  10. Yuen HKL, Mahesh L, Tse RKK, et al. Orbital Sclerosing Extramedullary Hematopoietic Tumor. Arch Ophthalmol. 2005;123:689–691. doi: https://doi.org/10.1001/archopht.123.5.689
  11. Sohawon D, Lau KK, Lau T, et al. Extra‐Medullary Haematopoiesis: A Pictorial Review of Its Typical and Atypical Locations. J Med Imaging Radiat Oncol. 2012;56(5):538–544. doi: https://doi.org/10.1111/j.1754‐9485.2012.02397.x
  12. Lin AL, Burnham JM, Pang V, et al. OCULAR MANIFESTATIONS OF PRIMARY MYELOFIBROSIS. Retin Cases Brief Rep. 2016;10(4):364–367. doi: https://doi.org/10.1097/ICB.0000000000000264
  13. Liisborg C, Hasselbalch HC, Sørensen TL. Ocular Manifestations in Patients with Philadelphia-Negative Myeloproliferative Neoplasms. Cancers (Basel). 2020;12(3):573. doi: https://doi.org/10.3390/cancers12030573
  14. Franchini M, Mannucci PM. The acquired von Willebrand syndrome: focused for hematologists. Haematologica, 2020;105(8):2032–2037. doi: https://doi.org/10.3324/haematol.2020.255117
  15. Na J, Choi SY, Baek S, et al. Hemorrhage and Infarction of the Conjunctiva and Orbit in Essential Thrombocythemia. J Craniofac Surg. 2017;28(3):750–751. doi: https://doi.org/10.1097/SCS.0000000000003431
  16. Юнусова Э.М., Бакиров Б.А., Мухамадеев Т.Р. Офтальмологические проявления хронических миелопролиферативных заболеваний // Медицинский вестник Башкортостана. — 2021. — Т. 16. — № 5. — С. 52–56. [Yunusova EM, Bakirov BA, Mukhamadeev TR. Ophthalmic manifestations of chronic myeloproliferative diseases. Bashkortostan Medical Journal. 2021;16(5):52–56. (In Russ.)]
  17. Rajagopal R, Apte RS. Seeing through Thick and through Thin: Retinal Manifestations of Thrombophilic and Hyperviscosity Syndromes. Surv Ophthalmol. 2016;61(2):236–247. doi: https://doi.org/10.1016/j.survophthal.2015.10.006
  18. de Lacerda JF, Oliveira SN, Ferro JM. Chronic Myeloproliferative Diseases. Handb Clin Neurol. 2014;120:1073–1081. doi: https://doi.org/10.1016/B978‐0‐7020‐4087‐0.00072‐3
  19. Vicini G, Nicolosi C, Malandrino D, Tozzetti, et al. Leukostasis retinopathy with leukemic infiltrates as onset manifestation of chronic myeloid leukemia: a case report. Eur J Ophthalmol. 2021;31(5):NP116–NP121. doi: https://doi.org/10.1177/1120672120930679
  20. Ganesan S, Raman R, Sharma T. Polycythemia Causing Posterior Segment Vascular Occlusions. Oman J Ophthalmol. 2017;10(1):33–35. doi: https://doi.org/10.4103/ojo.OJO_110_2014
  21. Dhrami‐Gavazi E, Lee W, Horowitz JD, et al. Jak2 Mutation‐Positive Polycythemia Vera Presenting as Central Retinal Artery Occlusion. Retin Cases Brief Rep. 2015;9(2):127–130. doi: https://doi.org/10.1097/ICB.0000000000000114
  22. Tache JE, Saffra N, Marshak H, et al. Retinal vein thrombosis as the presenting symptom of essential thrombocythemia. Am J Med Sci. 2005;329(3):139–140. doi: https://doi.org/10.1097/00000441-200503000-00005
  23. Rao K, Shenoy SB, Kamath Y, et al. Central retinal artery occlusion as a presenting manifestation of polycythaemia vera. BMJ Case Rep. 2016;2016:bcr2016216417. doi: https://doi.org/10.1136/bcr‐2016‐216417
  24. Rue KS, Hirsch LK, Sadun AA. Impending anterior ischemic optic neuropathy with elements of retinal vein occlusion in a patient on interferon for polycythemia vera. Clin Ophthalmol. 2012;6:1763–1765. doi: https://doi.org/10.2147/OPTH.S33456
  25. Wong WL, Su X, Li X, et al. Global prevalence of age‐related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta‐analysis. Lancet Glob Heal. 2014;2(2):e106–e116. doi: https://doi.org/10.1016/S2214‐109X(13)70145‐1
  26. Grunwald JE, Metelitsina TI, DuPont JC, et al. Reduced Foveolar Choroidal Blood Flow in Eyes with Increasing AMD Severity. Invest Opthalmol Vis Sci. 2005;46(3):1033. doi: https://doi.org/10.1167/iovs.04‐1050
  27. Coleman DJ, Silverman RH, Rondeau MJ, Lloyd HO, et al. Age‐Related Macular Degeneration: Choroidal Ischaemia? Br. J. Ophthalmol. 2013;97(8):1020–1023. doi: https://doi.org/10.1136/bjophthalmol‐2013‐303143
  28. Pekel G, Doğu MH, Keskin A, et al. Subfoveal Choroidal Thickness Is Associated with Blood Hematocrit Level. Ophthalmologica. 2015;234(1):55–59. doi: https://doi.org/10.1159/000433449
  29. Pekel G, Doğu MH, Sari HI, et al. Retinal Vessel Caliber, Choroidal Thickness and Ocular Pulse Amplitude Measurements in Essential Thrombocythemia. Middle East Afr J Ophthalmol. 2016;23(1):84–88. doi: https://doi.org/10.4103/0974‐9233.171827
  30. Havelius U, Berglund S, Falke P, et al. Impaired Dark Adaptation in Polycythemia. Improvement after Treatment. Acta Ophthalmol Scand. 2000;78(1):53–57. doi: https://doi.org/10.1034/j.1600-0420.2000.078001053.x
  31. Thandra A, Jun B, Chuquilin M. Papilloedema and Increased Intracranial Pressure as a Result of Unilateral Jugular Vein Thrombosis. Neuroophthalmology. 2015;39(4):179–182. doi: https://doi.org/10.3109/01658107.2015.1044541
  32. Sharma PV, Ilyas O, Jobanputra Y, et al. Is it always cancer? A curious case of benign intracranial hypertension in chronic myeloid leukemia. Intractable Rare Dis Res. 2018;7(3):182–184. doi: https://doi.org/10.5582/irdr.2018.01045
  33. Юнусова Э.М., Мухамадеев Т.Р., Бакиров Б.А. Оценка частоты глазных изменений и качества жизни пациентов при хронических миелопролиферативных заболеваниях // Вестник Российского государственного медицинского университета. — 2022. — № 3. — С. 86–90. [Yunusova EM, Muhamadeev TR, Bakirov BA. Ocenka chastoty glaznyh izmenenij i kachestva zhizni pacientov pri hronicheskih mieloproliferativnyh zabolevaniyah. Vestnik Rossijskogo gosudarstvennogo medicinskogo universiteta. 2022;3:86–90. (In Russ.)] doi: https://doi.org/10.24075/vrgmu.2022.027

Supplementary files

There are no supplementary files to display.


Copyright (c) 2023 "Paediatrician" Publishers LLC

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies